NEW YORK, Aug. 30, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Global Acute Myeloid Leukemia (AML) Therapeutics Industry
This report analyzes the worldwide markets for Acute Myeloid Leukemia (AML) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. European market for AML Therapeutics is further analyzed by the following countries/regions - France, Germany, Italy, UK, and Rest of Europe. Annual estimates and forecasts are provided for the period 2009 through 2018. The report profiles 68 companies including many key and niche players such as Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals, Inc., Bio-Path Holdings, Inc., BioSante Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals, Inc., EpiCept Corp., Genzyme Corporation, Lorus Therapeutics, Inc., Novartis AG, Onconova Therapeutics, Inc., and Sunesis Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
To order this report:Pathology Industry: Global Acute Myeloid Leukemia (AML) Therapeutics Industry
Intl: +1 805-652-2626